Keros Therapeutics (KROS) Revenue & Revenue Breakdown
Keros Therapeutics Revenue Highlights
Latest Revenue (Y)
$151.00K
Latest Revenue (Q)
$83.00K
Main Segment (Y)
License
Keros Therapeutics Revenue by Period
Keros Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $151.00K | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $20.10M | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2019-12-31 | $10.00M | - |
| 2018-12-31 | $10.00M | - |
Keros Therapeutics generated $151.00K in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 1.51% compared to the same period a year ago.
Keros Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $83.00K | -41.96% |
| 2023-12-31 | $143.00K | 1687.50% |
| 2023-09-30 | $8.00K | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | -100.00% |
| 2022-06-30 | $100.00K | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $20.00M | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $100.00K | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | -100.00% |
| 2020-09-30 | $2.50M | - |
| 2020-06-30 | $2.50M | - |
| 2020-03-31 | $2.50M | - |
| 2019-12-31 | $2.50M | - |
| 2019-09-30 | $2.50M | - |
| 2019-06-30 | $2.50M | - |
| 2019-03-31 | $2.50M | - |
Keros Therapeutics generated $83.00K in revenue during Q1 2024, up -41.96% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Keros Therapeutics Revenue Breakdown
Keros Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 |
|---|---|---|
| License | $144.00M | $144.00M |
Keros Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: License (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Jun 23 | Mar 23 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|
| Service, Other | $83.00K | - | - | - | - | - | - | - |
| License | - | $144.00M | $144.00M | $144.00M | $144.00M | $18.00M | $20.00M | $100.00K |
Keros Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Service, Other (100.00%).
Keros Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $172.81M |
| IDYA | IDEAYA Biosciences | $23.39M | - |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| ANAB | AnaptysBio | $17.16M | $10.97M |
| MGTX | MeiraGTx | $14.02M | $282.00K |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| KZR | Kezar Life Sciences | $7.00M | - |
| IPSC | Century Therapeutics | $2.23M | $771.00K |
| FIXX | Q32 Bio | $1.16M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| AVTE | Aerovate Therapeutics | - | - |
| NGM | NGM Biopharmaceuticals | - | $165.00K |
| REPL | Replimune Group | - | - |
| ERAS | Erasca | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| MLYS | Mineralys Therapeutics | - | - |
| LRMR | Larimar Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |
| SRZN | Surrozen | - | - |
KROS Revenue FAQ
What is Keros Therapeutics’s yearly revenue?
Keros Therapeutics's yearly revenue for 2023 was $151K, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. KROS's yearly revenue for 2021 was $20.1M, representing an increase of 100.00% compared to 2020.
What is Keros Therapeutics’s quarterly revenue?
Keros Therapeutics's quarterly revenue for Q1 2024 was $83K, a -41.96% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $143K, a 1687.50% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). KROS's quarterly revenue for Q3 2023 was $8K, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Keros Therapeutics’s revenue growth rate?
Keros Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -99.25%, and for the last 5 years (2019-2023) was -98.49%.
What are Keros Therapeutics’s revenue streams?
Keros Therapeutics's revenue streams in c 22 are License
What is Keros Therapeutics’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Keros Therapeutics was License. This segment made a revenue of $144M, representing 100.00% of the company's total revenue.